Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-21
2011-06-21
Jarrell, Noble (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07964632
ABSTRACT:
This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
REFERENCES:
patent: 5688826 (1997-11-01), Massey et al.
patent: 5958960 (1999-09-01), Massey et al.
patent: 6316498 (2001-11-01), Nakazato et al.
patent: 6333428 (2001-12-01), Nakazato et al.
patent: 6716452 (2004-04-01), Piccariello et al.
patent: 6770676 (2004-08-01), Nakazato et al.
patent: 7067507 (2006-06-01), Pulley et al.
patent: 7371872 (2008-05-01), Moher et al.
patent: 2005/0192273 (2005-09-01), Johnson et al.
patent: 2008/0182889 (2008-07-01), Moher et al.
patent: 1459765 (2004-09-01), None
patent: 93/06127 (1993-04-01), None
patent: 98/04277 (1998-02-01), None
patent: 99/38839 (1999-08-01), None
patent: 00/12464 (2000-03-01), None
patent: 02/00605 (2002-01-01), None
patent: 02/34237 (2002-05-01), None
patent: 02/055481 (2002-07-01), None
patent: 02/055485 (2002-07-01), None
patent: 03/061698 (2003-07-01), None
patent: 03/084610 (2003-10-01), None
patent: 03/104217 (2003-12-01), None
“A Study for Patients with Schizophrenia”, http://clinicaltrials.gov/ct2/show?term=schizophrenia+AND+LY+2140023&rank=2, accessed Sep. 20, 2010.
Neugebauer et al. Expert Opinion on Therapeutic Targets, 2002, 6(3), 349-61.
Jaeschke. Expert Opinion on Therapeutic Patents, 2008, 18(2), pp. 123-142.
“Can schizophrenia be prevented”, http://www.neuropsychiatryreviews.com/dec00
pr—dec00—schizo.html, accessed May 28, 2009.
Han et al. Molecular Pain, 2006, 2:18, pp. 1-12.
Cartmell, J., et al., “Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine,” Psychopharmacology (2000) 148:423-429.
Cartmell, J., et al., “The Metabotropic Glutamate 2/3 Receptor Agonists LY354740 and LY379268 Selectively Attenuate Phencyclidine versus d-Amphetamine Motor Behaviors in Rats,” JPET 291.161-170, 1999.
Helton, et al., “Anxiolytic and Side-Effect Profile of LY354740: A Potent, Highly Selective, Orally Active Agonist for Group II Metabotropic Glutamate Receptors,” JPET 284:651-660, 1998.
Klodzinska, et al., “Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models,” Neuropharmacology 38 (1999) 1831-1839.
Konieczny, et al., “LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats,” Naunyn-Schmiedeberg's Arch Pharmacol (1998) 358:500-502.
Matarredona, et al., “Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+-induced neurotoxicity along with brain-derived neurotrophic factor induction,” Journal of Neurochemistry, 2001, 76, 351-360.
Shekhar, et al., “LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats,” Neuropharmacology 39 (2000) 1139-1146.
Simmons, R., et al., “Group II mGluR receptor agonists are effective in persistent and neuropathic pain models in rats,” Pharmacology, Biochemistry and Behavior 73 (2002) 419-427.
Bradshaw, T., et al., “Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl) benzothiazoles,” Molecular Cancer Therapeutics, 1(4):239-246 (Feb. 2002).
Dantzig, A.H., et al., “Uptake of the cephalosporin, cephalexin, by a dipeptide transport carrier in the human intestinal cell line, Caco-2.” Biochimica et Biophysica Acta, 1027:211-217 (1990).
Han, H.K., “Targeted Prodrug Design to Optimize Drug Delivery,” AAPS Pharmsci, 2(1), article 6 (2000).
Han, H.K., et al. “Designing Prodrugs for the HPEPT1 Transporter,” College of Pharmacy, The University of Michigan, pp. 1259-1260, 2000.
Hu, M., et al., “Use of the Peptide Carrier System to Improve the Inestinal Absorption of L-a-Methyldopa: Carrier Kinetics, Intestinal Permeabilities, and in Vitro Hydrolysis of Dipeptidyl Derivatives of L-a-Methyldopa,” Pharmaceutical Research, vol. 6, No. 1 (1989).
Meredith, D., et al., “modified amino acids and peptides as substrates for the intestinal peptide transporter PepT1,” Eur. J. Biochem, 267:3723-3728 (2000).
Monn, et al., Synthesis and Metabotropic Glutamate Receptor Activity of S-Oxidized Variants of (−)-4-Amino-2-Thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: Identification of Potent, Selective, and Orally Bioavailable Agonists for mGlu2/3 Receptors. Journal of Medicinal Chemistry,50:233-240 (2007).
Ohsumi, K., et al., “Synthesis and antitumor activities of amino acid prodrugs of amino-combretastatins,” Anti-Cancer Drug Design, 14:539-548 (1999).
Sanchez, J., et al., “Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinylquinolines, highly soluble quinolone prodrug with in vivo pseudomonas activity,” Journal of Medicinal Chemistry, 35(10):1764-1773 (1992).
Sawada, K., et al., “Recognition of L-Amino Acid Ester Compounds by Rat Peptide Transporters PEPT1 and PEPT2,” The Journal of Pharmacology and Experimental Therapeutics, 291(2):705 (1999).
Wang, H.P., et al., “Synthesis and Pharmacological Activities of a Novel Tripeptide Mimetic Dopamine Prodrug,” Bioorganic & Medicinal Chemistry Letters, 5(19):2195-2198 (1995).
Yang, C.Y., et al., “Intestinal Peptide Transport Systems and Oral Drug Availability,” Pharmaceutical Research, 16 (9):1331-1343 (1999).
Yang, C., et al., “Prodrug based optimal drug delivery via membrane transporter/receptor,” Exp. Opin. Biol. Ther., 1 (2):159-175 (2001).
“Amino acids, cyclic,” http://www.nlm.nih.gov/cgi/mesh/2009/MB—cgi?mode=&term=Amino+Acids,+Cyclic&field=entry#TreeD12.125.072, accessed Feb. 19, 2009.
Blanco-Urgoiti Jaime Gonzalo
Collado Caño Ivan
Moher Eric David
Monn James Allen
Pedregal-Tercero Concepcion
Demeter John C.
Eli Lilly and Company
Hostettler Danica
Jarrell Noble
LandOfFree
Methods of treatment using a prodrug of an excitatory amino... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treatment using a prodrug of an excitatory amino..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment using a prodrug of an excitatory amino... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2695229